Recent advances in molecular biology have led to the development of novel small molecules
that target specific viral proteins of the hepatitis C virus (HCV) life cycle. These drugs, …

Background In patients with chronic hepatitis C virus, liver biopsy is the gold standard for
assessing liver disease stage; nevertheless, it is prone to complications, some of them serious. …

OBJECTIVES Fibrotest (FT) and Actitest (AT) are biochemical markers of fibrosis and activity
for use as a non-invasive alternative to liver biopsy in patients with chronic hepatitis C virus (…

FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients with chronic hepatitis
C (CHC) and subsequently assessed in other frequent liver diseases, including chronic …

DNA methylation of retroviral promoters and enhancers localized in the provirus 5′ long
terminal repeat (LTR) is considered to be a mechanism of transcriptional suppression that …

Background FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients with
chronic hepatitis C (CHC). The aim was to test two hypotheses, one, that the FT diagnostic …

For HCV infection, there have been major advancements during last several years with large
numbers of ongoing trials with various direct‐acting antivirals ( DAA ) showing high potency…

Natural killer (NK) cells are affected by infection with human cytomegalovirus (HCMV)
manifested by increased expression of the HLA‐E binding activating receptor NKG2C. We here …

Background: The area under the ROC curve (AUC) is widely used as an estimate of the
diagnostic value for fibrosis markers. Whether there is variability in the AUC related to the …

The staging of liver fibrosis is pivotal for defining the prognosis and indications for therapy in
hepatitis C. Although liver biopsy remains the gold standard, several noninvasive methods …